Quartz
중도 성향
산업/기업
부정적Pfizer's monthly weight loss shot posted side effects similar to Wegovy in mid-stage trial
Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly shot
Quartz · "LOSS" · 총 13건
필터 보기현재 지수
51.1
0 = 부정 우세
50 = 중립
100 = 긍정 우세
최근 7일 기준 219건을 분석한 결과, 뉴스 심리지수는 51.1(균형)입니다. 긍정 31건(14.2%)·중립 173건(79.0%)·부정 15건(6.8%)이며, 중립 비중이 뚜렷하게 높습니다. 성향 지수는 종합 0.0(중도 균형)입니다.
Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly shot
More than 80% of new Wegovy pill prescriptions are for patients who had never previously taken a GLP-1 drug
Participants on the highest dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks, Lilly said
From Japanese mountains cloaked in cherry blossoms to Icelandic valleys under midnight sun, these 15 destinations transform so dramatically across seasons they almost seem like different places
The pet retailer posted a net loss of $15.1 million in the first quarter, wider than a year ago, even as comparable sales rose 0.7%
A launch in the United Arab Emirates comes as Novo works to recover ground in the weight loss drug market against rival Eli Lilly
The rollout comes after two legal losses for Meta in child safety cases, including a $375 million verdict in New Mexico
From Japan's bamboo forests and cherry blossoms to Iceland's geysers, glaciers, and northern lights, the world's most naturally beautiful countries
The company raised its full-year chicken income forecast to as much as $2.05 billion and lifted its total adjusted operating income outlook
The six-month clinical study will enroll 100 adults starting weight-loss drug therapy to test whether smartwatch data can help manage muscle loss
Net earnings fell to $83.1 million from $367.1 million as rental truck depreciation rose by $186.6 million and disposal losses hit $117.6 million for the year
The department store chain lost 13 cents per share in its fiscal first quarter, beating analyst expectations of a 19-cent loss
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options